BioCentury | Sep 15, 2003
Financial News

U3 Pharma raises EUR 13.3M

Cancer company U3 Pharma (Martinsried, Germany) raised EUR 13.3 million ($14.7 million) in a series B round co-led by Atlas Venture and LCF Rothschild. Other investors included BioMedical Sciences Investment Fund; Alta Partners; BioM; and...
BioCentury | Mar 18, 2002
Emerging Company Profile

Corporate Profile

U3 Pharma AG Martinsried, Germany Technology: TASC target selection technology Disease focus: Cancer, non-malignant proliferative diseases Clinical status: Preclinical Founded: 2001 by Axel Ullrich Corporate partners: NA University collaborators: Max-Planck-Institute for Biochemistry Number of employees:...
BioCentury | Oct 22, 2001
Company News

New signal transduction company

...it raised EUR5 million ($4.5 million) in a venture financing. Investors included Alta Partners; and Medicis Ventures. BC...
BioCentury | Oct 9, 2000
Finance

Beware the ides of October

The biotech industry last week joined its high tech compatriots with earnings warnings - some from companies, and some from sellside analysts - and the prophesies knocked $4.3 billion off the valuation of three companies (see ("Earning...
Items per page:
1 - 4 of 4
BioCentury | Sep 15, 2003
Financial News

U3 Pharma raises EUR 13.3M

Cancer company U3 Pharma (Martinsried, Germany) raised EUR 13.3 million ($14.7 million) in a series B round co-led by Atlas Venture and LCF Rothschild. Other investors included BioMedical Sciences Investment Fund; Alta Partners; BioM; and...
BioCentury | Mar 18, 2002
Emerging Company Profile

Corporate Profile

U3 Pharma AG Martinsried, Germany Technology: TASC target selection technology Disease focus: Cancer, non-malignant proliferative diseases Clinical status: Preclinical Founded: 2001 by Axel Ullrich Corporate partners: NA University collaborators: Max-Planck-Institute for Biochemistry Number of employees:...
BioCentury | Oct 22, 2001
Company News

New signal transduction company

...it raised EUR5 million ($4.5 million) in a venture financing. Investors included Alta Partners; and Medicis Ventures. BC...
BioCentury | Oct 9, 2000
Finance

Beware the ides of October

The biotech industry last week joined its high tech compatriots with earnings warnings - some from companies, and some from sellside analysts - and the prophesies knocked $4.3 billion off the valuation of three companies (see ("Earning...
Items per page:
1 - 4 of 4